Examkin

Question

Difficulty: MediumRheumatology and Immunology

A 41-year-old woman recently diagnosed with limited cutaneous systemic sclerosis seeks care for progressively worsening color changes and throbbing pain in her fingers upon cold exposure. Over several years, her symptoms progressively escalate despite compliance with each prescribed treatment regimen, eventually leading to severe digital ischemia and impending gangrene. Arrange the following therapies for secondary Raynaud phenomenon in the standard stepwise order of clinical escalation, from initial baseline management to interventions for medically refractory, limb-threatening disease.

  1. 1Implementation of behavioral modifications, including strict cold avoidance and smoking cessation
  2. 2Initiation of an oral dihydropyridine calcium channel blocker (e.g., nifedipine)
  3. 3Addition of a phosphodiesterase-5 (PDE-5) inhibitor (e.g., sildenafil)
  4. 4Administration of an intravenous prostanoid (e.g., epoprostenol)
  5. 5Performance of a digital sympathectomy

Answer

The correct chronological sequence of therapy escalation is: behavioral modifications, followed by oral calcium channel blockers, followed by oral PDE-5 inhibitors, then intravenous prostanoids, and finally digital sympathectomy.
The management of secondary Raynaud phenomenon follows a strict stepwise escalation to balance efficacy with medication side effects and procedural risks. Treatment always begins with nonpharmacologic behavioral modifications. If vasospastic attacks continue, oral vasodilators are introduced, starting with dihydropyridine calcium channel blockers. If symptoms remain refractory, secondary oral agents like PDE-5 inhibitors are added. Progression to severe ischemic complications, such as digital ulcers, mandates escalation to intravenous prostanoids. Finally, if tissue loss is imminent and all medical therapies fail, surgical sympathectomy is performed.

Step-by-Step Solution

1
Identify the initial baseline management for Raynaud phenomenon.
Behavioral modifications are selected as the first step.
Keeping the core and extremities warm while avoiding triggers like smoking is a mandatory, non-invasive baseline for all patients.
2
Determine the first-line pharmacologic escalation.
Oral dihydropyridine calcium channel blockers are selected as the second step.
When non-pharmacologic measures fail, calcium channel blockers like nifedipine are the safest and most effective initial oral vasodilators.
3
Identify the next step for inadequate response to initial pharmacotherapy.
Addition of a PDE-5 inhibitor is selected as the third step.
Additional oral agents such as sildenafil are added to maximize vasodilation before resorting to invasive or intravenous options.
4
Determine the management for severe complications like digital ulcers.
Intravenous prostanoids are selected as the fourth step.
Active tissue ischemia or ulceration demands potent, systemic therapies like intravenous epoprostenol.
5
Identify the treatment of last resort for limb-threatening disease.
Digital sympathectomy is selected as the final step.
Surgical intervention is highly invasive and is reserved for imminent gangrene when all medical therapies have been exhausted.

Key Concept

Stepwise escalation of therapy for secondary Raynaud phenomenon in systemic sclerosis.
Rate this question

Topics

Rheumatology and Immunology

More questions from this topic